Novo Nordisk A/S (NVO) Return on Equity (ROE): 60.74%
Is Novo Nordisk A/S’s return on equity (ROE) high or low?
Novo Nordisk A/S's return on equity (ROE) of 60.74% is 51% below its 5-year average of 123.42%, near the low end of its 5-year range (52.79%–404.81%).
As of Wednesday, June 17, 2026. 1.37% below its 12-month average of 61.58%.
NVO Return on Equity (ROE) Chart
NVO Average Return on Equity (ROE) Chart
NVO Current vs Average Return on Equity (ROE) Chart
NVO Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
60.74%
RETURN ON EQUITY (ROE) AVG TTM
61.58%
RETURN ON EQUITY (ROE) AVG 3Y
67.05%
RETURN ON EQUITY (ROE) AVG 5Y
123.42%
RETURN ON EQUITY (ROE) AVG 10Y
136.35%
RETURN ON EQUITY (ROE) AVG 15Y
64.79%
RETURN ON EQUITY (ROE) AVG 20Y
54.50%
CURRENT VS TTM AVG
-1.37%
CURRENT VS 3Y AVG
-9.41%
CURRENT VS 5Y AVG
-50.79%
CURRENT VS 10Y AVG
-55.45%
CURRENT VS 15Y AVG
-6.25%
CURRENT VS 20Y AVG
+11.45%
NVO Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.39B | 60.74% | 61.58% | 67.05% | 123.42% |
| Amgen Inc. (AMGN)vs › | $187.59B | 84.87% | 79.33% | 111.35% | 101.76% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 13.21% | 12.70% | 13.51% | 15.24% |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 39.19% | 19.98% | 21.60% | 19.44% |
| Abbott Laboratories (ABT)vs › | $157.84B | 12.06% | 20.32% | 18.59% | 17.97% |
| Pfizer Inc. (PFE)vs › | $148.41B | 8.31% | 9.04% | 13.32% | 16.07% |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 17.05% | 15.07% | 13.91% | 13.46% |
| Danaher Corporation (DHR)vs › | $128.06B | 6.97% | 7.38% | 9.51% | 10.24% |
| CVS Health Corporation (CVS)vs › | $127.73B | 3.79% | 4.23% | 6.35% | 7.74% |
| Stryker Corporation (SYK)vs › | $115.45B | 14.52% | 14.50% | 15.05% | 14.30% |
Return Analysis
ROE
60.7%
ROA
22.1%
Novo Nordisk A/S Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Novo Nordisk A/S (NVO)?
- The return on equity (ROE) for NVO stock is 60.74%.
- Is Novo Nordisk A/S's return on equity (ROE) high or low?
- Novo Nordisk A/S's return on equity (ROE) of 60.74% is 51% below its 5-year average of 123.42%, near the low end of its 5-year range (52.79%–404.81%).
- What is the TTM average return on equity (ROE) for Novo Nordisk A/S (NVO)?
- The TTM average return on equity (ROE) for NVO stock is 61.58%.
- What is the 3Y average return on equity (ROE) for Novo Nordisk A/S (NVO)?
- The 3Y average return on equity (ROE) for NVO stock is 67.05%.
- What is the 5Y average return on equity (ROE) for Novo Nordisk A/S (NVO)?
- The 5Y average return on equity (ROE) for NVO stock is 123.42%.
- What is the 10Y average return on equity (ROE) for Novo Nordisk A/S (NVO)?
- The 10Y average return on equity (ROE) for NVO stock is 136.35%.
- What is the 15Y average return on equity (ROE) for Novo Nordisk A/S (NVO)?
- The 15Y average return on equity (ROE) for NVO stock is 64.79%.
- What is the 20Y average return on equity (ROE) for Novo Nordisk A/S (NVO)?
- The 20Y average return on equity (ROE) for NVO stock is 54.50%.
Novo Nordisk A/S Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 52.79% |
| 2024-12-31 | 70.38% |
| 2023-12-31 | 78.53% |
| 2022-12-31 | 66.51% |
| 2021-12-31 | 67.50% |
| 2020-12-31 | 404.81% |
| 2019-12-31 | 450.22% |
| 2018-12-31 | 74.52% |
| 2017-12-31 | 76.54% |
| 2016-12-31 | 83.78% |
| 2015-12-31 | 74.22% |
| 2014-12-31 | 65.72% |
| 2013-12-31 | 59.16% |
| 2012-12-31 | 52.75% |
| 2011-12-31 | 45.66% |
| 2010-12-31 | 38.96% |
| 2009-12-31 | 30.13% |
| 2008-12-31 | 29.24% |
| 2007-12-31 | 26.49% |
| 2006-12-31 | 21.42% |
| 2005-12-31 | 21.22% |
| 2004-12-31 | 18.92% |
| 2003-12-31 | 19.26% |
| 2002-12-31 | 17.87% |
| 2001-12-31 | 19.18% |
| 2000-12-31 | 19.61% |
| 1999-12-31 | 13.03% |
| 1998-12-31 | 13.43% |
| 1997-12-31 | 12.25% |
| 1996-12-31 | 11.26% |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar